In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|August 30, 2022
Emerson Opens Gas Analysis Solutions Center in Scotland
Author(s)BioPharm International Editors
Emerson’s new gas analysis solutions center, located in Cumbernauld, Scotland, intends to help plants meet sustainability goals.
Advertisement
Emerson announced the opening of a gas analysis solutions facility in Cumbernauld, Scotland on Aug. 29, 2022. The 62,000 ft² facility is designed to help companies reduce their environmental impact.
According to a company press release, the center has access to more than 10 different sensing technologies that can measure more than 60 different gas components. It will also engineer and manufacture Emerson’s Rosemount continuous gas analyzers and gas chromatographers, which are tools designed to improve monitoring emissions, plant safety, quality control, and operational efficiency.
“The mission of our new gas analysis solutions center is to support industrial manufacturers in achieving their decarbonization and environmental sustainability goals, including the deployment of low-carbon fuels and power sources, reducing emissions, and decreasing waste,” said Jon Stokes, group president of Emerson’s measurement solutions business, in the release. “It’s the latest addition to our investment in innovation that will help to achieve a more sustainable future.”
The facility has a gas extraction system, environmental chamber, and an external gas storage to facilitate gas analyzer testing, as well as application research and development. It includes a training space and offers various training options for customers, including in-person and web-based courses. It also has a dedicated area for performing factory acceptance testing and a customer collaboration space.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5